Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study
Abstract Background Peripheral artery disease (PAD) is recognized as a significant predictor of mortality and adverse cardiovascular outcomes in patients with coronary heart disease (CHD). In fact, coexisting PAD and CHD is strongly associated with a greater coronary event recurrence compared with e...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-03-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-021-01260-3 |
| _version_ | 1830299336566636544 |
|---|---|
| author | Elena M. Yubero-Serrano Juan F. Alcalá-Diaz Francisco M. Gutierrez-Mariscal Antonio P. Arenas-de Larriva Patricia J. Peña-Orihuela Ruth Blanco-Rojo Javier Martinez-Botas Jose D. Torres-Peña Pablo Perez-Martinez Jose M. Ordovas Javier Delgado-Lista Diego Gómez-Coronado Jose Lopez-Miranda |
| author_facet | Elena M. Yubero-Serrano Juan F. Alcalá-Diaz Francisco M. Gutierrez-Mariscal Antonio P. Arenas-de Larriva Patricia J. Peña-Orihuela Ruth Blanco-Rojo Javier Martinez-Botas Jose D. Torres-Peña Pablo Perez-Martinez Jose M. Ordovas Javier Delgado-Lista Diego Gómez-Coronado Jose Lopez-Miranda |
| author_sort | Elena M. Yubero-Serrano |
| collection | DOAJ |
| description | Abstract Background Peripheral artery disease (PAD) is recognized as a significant predictor of mortality and adverse cardiovascular outcomes in patients with coronary heart disease (CHD). In fact, coexisting PAD and CHD is strongly associated with a greater coronary event recurrence compared with either one of them alone. High-density lipoprotein (HDL)-mediated cholesterol efflux capacity (CEC) is found to be inversely associated with an increased risk of incident CHD. However, this association is not established in patients with PAD in the context of secondary prevention. In this sense, our main aim was to evaluate the association between CEC and PAD in patients with CHD and whether the concurrent presence of PAD and T2DM influences this association. Methods CHD patients (n = 1002) from the CORDIOPREV study were classified according to the presence or absence of PAD (ankle-brachial index, ABI ≤ 0.9 and ABI > 0.9 and < 1.4, respectively) and T2DM status. CEC was quantified by incubation of cholesterol-loaded THP-1 cells with the participants' apoB-depleted plasma was performed. Results The presence of PAD determined low CEC in non-T2DM and newly-diagnosed T2DM patients. Coexisting PAD and newly-diagnosed T2DM provided and additive effect providing an impaired CEC compared to non-T2DM patients with PAD. In established T2DM patients, the presence of PAD did not determine differences in CEC, compared to those without PAD, which may be restored by glucose-lowering treatment. Conclusions Our findings suggest an inverse relationship between CEC and PAD in CHD patients. These results support the importance of identifying underlying mechanisms of PAD, in the context of secondary prevention, that provide potential therapeutic targets, that is the case of CEC, and establishing strategies to prevent or reduce the high risk of cardiovascular events of these patients. Trial registration https://clinicaltrials.gov/ct2/show/NCT00924937 . Unique Identifier: NCT00924937 |
| first_indexed | 2024-12-19T08:07:30Z |
| format | Article |
| id | doaj.art-eea509632b1f4d93ad7cd5df929fe9c3 |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-12-19T08:07:30Z |
| publishDate | 2021-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-eea509632b1f4d93ad7cd5df929fe9c32022-12-21T20:29:44ZengBMCCardiovascular Diabetology1475-28402021-03-0120111010.1186/s12933-021-01260-3Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV studyElena M. Yubero-Serrano0Juan F. Alcalá-Diaz1Francisco M. Gutierrez-Mariscal2Antonio P. Arenas-de Larriva3Patricia J. Peña-Orihuela4Ruth Blanco-Rojo5Javier Martinez-Botas6Jose D. Torres-Peña7Pablo Perez-Martinez8Jose M. Ordovas9Javier Delgado-Lista10Diego Gómez-Coronado11Jose Lopez-Miranda12Lipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaLipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaLipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaLipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaLipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaResearch and Development Department, Biosearch LifeCIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos IIILipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaLipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaJean Mayer US Department of Agriculture Human Nutrition Research Center On Aging, Tufts University School of MedicineLipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaCIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos IIILipids and Atherosclerosis Unit. Servicio de Medicina Interna, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research in Córdoba, University of CórdobaAbstract Background Peripheral artery disease (PAD) is recognized as a significant predictor of mortality and adverse cardiovascular outcomes in patients with coronary heart disease (CHD). In fact, coexisting PAD and CHD is strongly associated with a greater coronary event recurrence compared with either one of them alone. High-density lipoprotein (HDL)-mediated cholesterol efflux capacity (CEC) is found to be inversely associated with an increased risk of incident CHD. However, this association is not established in patients with PAD in the context of secondary prevention. In this sense, our main aim was to evaluate the association between CEC and PAD in patients with CHD and whether the concurrent presence of PAD and T2DM influences this association. Methods CHD patients (n = 1002) from the CORDIOPREV study were classified according to the presence or absence of PAD (ankle-brachial index, ABI ≤ 0.9 and ABI > 0.9 and < 1.4, respectively) and T2DM status. CEC was quantified by incubation of cholesterol-loaded THP-1 cells with the participants' apoB-depleted plasma was performed. Results The presence of PAD determined low CEC in non-T2DM and newly-diagnosed T2DM patients. Coexisting PAD and newly-diagnosed T2DM provided and additive effect providing an impaired CEC compared to non-T2DM patients with PAD. In established T2DM patients, the presence of PAD did not determine differences in CEC, compared to those without PAD, which may be restored by glucose-lowering treatment. Conclusions Our findings suggest an inverse relationship between CEC and PAD in CHD patients. These results support the importance of identifying underlying mechanisms of PAD, in the context of secondary prevention, that provide potential therapeutic targets, that is the case of CEC, and establishing strategies to prevent or reduce the high risk of cardiovascular events of these patients. Trial registration https://clinicaltrials.gov/ct2/show/NCT00924937 . Unique Identifier: NCT00924937https://doi.org/10.1186/s12933-021-01260-3Peripheral artery diseaseType 2 diabetes mellitusCholesterol efflux capacityCoronary heart diseaseSecondary prevention |
| spellingShingle | Elena M. Yubero-Serrano Juan F. Alcalá-Diaz Francisco M. Gutierrez-Mariscal Antonio P. Arenas-de Larriva Patricia J. Peña-Orihuela Ruth Blanco-Rojo Javier Martinez-Botas Jose D. Torres-Peña Pablo Perez-Martinez Jose M. Ordovas Javier Delgado-Lista Diego Gómez-Coronado Jose Lopez-Miranda Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study Cardiovascular Diabetology Peripheral artery disease Type 2 diabetes mellitus Cholesterol efflux capacity Coronary heart disease Secondary prevention |
| title | Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study |
| title_full | Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study |
| title_fullStr | Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study |
| title_full_unstemmed | Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study |
| title_short | Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study |
| title_sort | association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes from the cordioprev study |
| topic | Peripheral artery disease Type 2 diabetes mellitus Cholesterol efflux capacity Coronary heart disease Secondary prevention |
| url | https://doi.org/10.1186/s12933-021-01260-3 |
| work_keys_str_mv | AT elenamyuberoserrano associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT juanfalcaladiaz associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT franciscomgutierrezmariscal associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT antonioparenasdelarriva associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT patriciajpenaorihuela associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT ruthblancorojo associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT javiermartinezbotas associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT josedtorrespena associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT pabloperezmartinez associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT josemordovas associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT javierdelgadolista associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT diegogomezcoronado associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy AT joselopezmiranda associationbetweencholesteroleffluxcapacityandperipheralarterydiseaseincoronaryheartdiseasepatientswithandwithouttype2diabetesfromthecordioprevstudy |